A bumper crop of revisions, including a stronger drug benefit, means the plan you enrolled in for 2024 may not be the best fit next year.
Market veteran Howard Marks cautions that China’s economic growth target is a ‘Herculean challenge’
Veteran investor Howard Marks is hopeful about China’s growth trajectory, though he believes a monumental feat lies ahead.